Frankfurt - Delayed Quote EUR

enVVeno Medical Corporation (5HJ.F)

3.2400
+0.0800
+(2.53%)
As of 8:09:26 AM GMT+2. Market Open.
Loading Chart for 5HJ.F
  • Previous Close 3.1600
  • Open 3.2400
  • Bid 3.2800 x --
  • Ask 3.3600 x --
  • Day's Range 3.2400 - 3.2400
  • 52 Week Range 1.8600 - 5.6000
  • Volume 100
  • Avg. Volume 1
  • Market Cap (intraday) 58.486M
  • Beta (5Y Monthly) 0.81
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0500
  • Earnings Date Jul 29, 2025 - Aug 4, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

www.envveno.com

37

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 5HJ.F

View More

Performance Overview: 5HJ.F

Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

5HJ.F
10.20%
S&P 500 (^GSPC)
1.39%

1-Year Return

5HJ.F
28.63%
S&P 500 (^GSPC)
11.05%

3-Year Return

5HJ.F
13.83%
S&P 500 (^GSPC)
47.57%

5-Year Return

5HJ.F
57.09%
S&P 500 (^GSPC)
102.07%

Compare To: 5HJ.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 5HJ.F

View More

Valuation Measures

As of 5/9/2025
  • Market Cap

    57.04M

  • Enterprise Value

    23.21M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.62

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.07%

  • Return on Equity (ttm)

    -52.88%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -21.33M

  • Diluted EPS (ttm)

    -1.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    38.94M

  • Total Debt/Equity (mrq)

    2.56%

  • Levered Free Cash Flow (ttm)

    -10.51M

Research Analysis: 5HJ.F

View More